Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention

• Verfasst von: Steg, Philippe Gabriel [VerfasserIn]
• Verfasst von: James, Stefan [VerfasserIn]
• Verfasst von: Harrington, Robert A. [VerfasserIn]
• Verfasst von: Ardissino, Diego [VerfasserIn]
• Verfasst von: Becker, Richard C. [VerfasserIn]
• Verfasst von: Cannon, Christopher P. [VerfasserIn]
• Verfasst von: Emanuelsson, Håkan [VerfasserIn]
• Verfasst von: Finkelstein, Ariel [VerfasserIn]
• Verfasst von: Husted, Steen [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Verfasst von: Kilhamn, Jan [VerfasserIn]
• Verfasst von: Olofsson, Sylvia [VerfasserIn]
• Verfasst von: Storey, Robert F. [VerfasserIn]
• Verfasst von: Weaver, W. Douglas [VerfasserIn]
• Verfasst von: Wallentin, Lars [VerfasserIn]
• Titel: Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention
• Verf.angabe: Philippe Gabriel Steg, MD, Stefan James, MD, PhD, Robert A. Harrington, MD, Diego Ardissino, MD, Richard C. Becker, MD, Christopher P. Cannon, MD, Håkan Emanuelsson, MD, PhD, Ariel Finkelstein, MD, Steen Husted, MD, DSc, Hugo Katus, MD, Jan Kilhamn, MD, PhD, Sylvia Olofsson, BSc, Robert F. Storey, MD, DM, W. Douglas Weaver, MD, Lars Wallentin, MD, PhD, and for the PLATO Study Group
• E-Jahr: 2010
• Jahr: 8 Nov 2010
• Umfang: 11 S.
• Fussnoten: Gesehen am 06.11.2023
• Titel Quelle: Enthalten in: Circulation
• Ort Quelle: Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950
• Jahr Quelle: 2010
• Band/Heft Quelle: 122(2010), 21, Seite 2131-2141
• ISSN Quelle: 1524-4539
• DOI: doi:10.1161/CIRCULATIONAHA.109.927582
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: acute coronary syndrome
• Sach-SW: hemorrhage
• Sach-SW: myocardial infarction
• Sach-SW: platelets
• Sach-SW: thrombosis
• K10plus-PPN: 1869420500

Abstract

Background— - - Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel and may be useful for patients with acute ST-segment elevation (STE) ACS and planned primary percutaneous coronary intervention. - - Methods and Result— - - Platelet Inhibition and Patient Outcomes (PLATO), a randomized, double-blind trial, compared ticagrelor with clopidogrel for the prevention of vascular events in 18 624 ACS patients. This report concerns the 7544 ACS patients with STE or left bundle-branch block allocated to either ticagrelor 180-mg loading dose followed by 90 mg twice daily or clopidogrel 300-mg loading dose (with provision for 300 mg clopidogrel at percutaneous coronary intervention) followed by 75 mg daily for 6 to 12 months. The reduction of the primary end point (myocardial infarction, stroke, or cardiovascular death) with ticagrelor versus clopidogrel (10.8% versus 9.4%; hazard ratio [HR], 0.87; 95% confidence interval, 0.75 to 1.01; P=0.07) was consistent with the overall PLATO results. There was no interaction between presentation with STE/left bundle-branch block and randomized treatment (interaction P=0.29). Ticagrelor reduced several secondary end points, including myocardial infarction alone (HR, 0.80; P=0.03), total mortality (HR, 0.82; P=0.05), and definite stent thrombosis (HR, 0.66; P=0.03). The risk of stroke, low in both groups, was higher with ticagrelor (1.7% versus 1.0%; HR,1.63; 95% confidence interval, 1.07 to 2.48; P=0.02). Ticagrelor did not affect major bleeding (HR, 0.98; P=0.76). - - Conclusion— - - In patients with STE-ACS and planned primary percutaneous coronary intervention, the effects of ticagrelor were consistent with those observed in the overall PLATO trial. - - Clinical Trial Registration— - - URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00391872.